Estimating the benefit of an HIV-1 vaccine that reduces viral load set point

Journal of Infectious Diseases

Volumn 195, Issue 4, 2007, Pages 546-550

  Gupta, Swati B ^a   Jacobson, Lisa P ^c   Margolick, Joseph B ^c   Rinaldo, Charles R ^b   Phair, John P ^d   Jamieson, Beth D ^e   Mehrotra, Devan V ^a   Robertson, Michael N ^a   Straus, Walter L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEROCONVERSION; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS LOAD;

AIDS VACCINES; COHORT STUDIES; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; MALE; REGRESSION ANALYSIS; TIME FACTORS; VIRAL LOAD;

EID: 33846830079     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510909     Document Type: Article

References (15)

1. Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer SM, Corey L. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis 2003; 188:179-93.
2. Munoz A, Xu J. Models for the incubation of AIDS: variations according to age and period. Stat Med 1996; 15:2459-73.
3. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
4. Lyles CM, Dorrucci M, Vlahov D, et al. Longitudinal human immunodeficiency virus type 1 load in the Italian seroconversion study: correlates and temporal trends of virus load. J Infect Dis 1999; 180:1018-24.
5. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335:1091-8.
6. Panel of Clinical Practices for Treatment of HIV Infection, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 4 February 2002. Available at: http://www.aidsinfo.nih.gov/guidelines. Accessed 1 October 2006.
7. Jacobson LP, Kirby AJ, Polk S, et al. Changes in survival after acquired immunodeficiency syndrome (AIDS): 1984-1991. Am J Epidemiol 1993; 138:952-64.
8. Kirstein LM, Mellors JW, Rinaldo CR, et al. Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma. J Clin Microbiol 1999; 37:2428-33.
9. Giorgi JV, Cheng HL, Margolick JB, et al. Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol 1990; 55:173-86.
10. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nat Med 1996; 2:625-9.
11. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347-55.
12. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-53.
13. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720-5.
14. Kanki PJ, Hamel DJ, Sankale JL. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179:68-73.
15. Napravnik S, Poole C, Thomas JC, Eron JJ. Gender difference in HIV RNA levels: a meta-analysis of published studies. JAIDS 2002; 31:11-9.